Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
RAPA-201 by Rapa Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
RAPA-201 is under clinical development by Rapa Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
Data Insights
RAPA-201 by Rapa Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
RAPA-201 is under clinical development by Rapa Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...